Revenue and Profit - Revenue for Q3 2024 reached ¥106,089,616.08, an increase of 40.22% compared to the same period last year[3] - Net profit attributable to shareholders was ¥22,764,523.64, a decrease of 3.09% year-on-year[3] - Net profit excluding non-recurring items was ¥14,572,117.46, down 24.96% from the previous year[3] - Total operating revenue for Q3 2024 reached CNY 293,304,171.94, an increase of 21.8% compared to CNY 240,653,628.05 in the same period last year[17] - Net profit for Q3 2024 was CNY 77,797,479.73, slightly up from CNY 77,311,464.53 year-over-year[18] - The net profit attributable to the parent company for Q3 2024 is CNY 77,797,479.73, compared to CNY 77,311,464.53 in the same period last year, showing a slight increase[19] - Basic and diluted earnings per share for Q3 2024 are both CNY 1.17, down from CNY 1.55 in the previous year[19] Cash Flow - Operating cash flow for the year-to-date was ¥32,913,587.68, a decline of 33.47% compared to the same period last year[9] - Cash inflow from operating activities for Q3 2024 is CNY 271,468,188.33, compared to CNY 227,101,965.12 in the same period last year, representing an increase of approximately 19.5%[21] - Cash outflow from operating activities for Q3 2024 is CNY 238,554,600.65, up from CNY 177,626,783.10 in the previous year, indicating a rise of about 34.3%[21] - The net cash flow from operating activities for Q3 2024 is CNY 32,913,587.68, down from CNY 49,475,182.02 in the same period last year, reflecting a decrease of approximately 33.4%[21] - Cash inflow from investing activities for Q3 2024 is CNY 586,466,383.06, significantly higher than CNY 128,757,260.74 in the previous year, marking an increase of about 355.5%[21] - Cash outflow from investing activities for Q3 2024 is CNY 668,447,895.14, compared to CNY 346,787,396.91 in the same period last year, which is an increase of approximately 92.5%[21] - The net cash flow from investing activities for Q3 2024 is -CNY 81,981,512.08, an improvement from -CNY 218,030,136.17 in the previous year[21] - The net cash flow from financing activities for Q3 2024 is -CNY 31,144,610.88, a significant decrease from CNY 1,034,075,946.06 in the same period last year[22] - The ending cash and cash equivalents balance for Q3 2024 is CNY 173,284,439.23, down from CNY 1,051,675,742.41 in the previous year, indicating a decrease of approximately 83.5%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,599,843,544.96, reflecting a 3.58% increase from the end of the previous year[3] - Total assets reached CNY 1,599,843,544.96, up from CNY 1,544,589,389.03, indicating overall growth in the company's asset base[17] - Total liabilities increased to CNY 91,369,640.14 from CNY 80,579,630.44, reflecting higher financial obligations[17] - The company’s total liabilities increased by 42.91% in accounts payable, reaching ¥38,617,305.36, primarily due to increased payments to clinical institutions[6] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,065[10] - The largest shareholder, Tao Chunlei, holds 39.64% of shares, totaling 26,427,800 shares[10] - The top ten shareholders include significant stakes from both individual and institutional investors, with the top four holding a combined 63.56%[12] - The company has a total of 50,861,136 restricted shares, with 6,267,886 shares released during the period[14] Research and Development - The company reported a significant increase in research and development expenses, which rose by 80.17% to ¥43,048,445.44 year-to-date[7] - Research and development expenses surged to CNY 43,048,445.44, compared to CNY 23,892,759.21 in the previous year, indicating a focus on innovation[18] Other Information - The company has no new product launches or technological developments reported in this quarter[12] - There are no mergers or acquisitions mentioned in the current report[12] - Future outlook and performance guidance were not explicitly detailed in the conference call[12] - Cash and cash equivalents decreased by 109.27% to a net decrease of ¥80,212,535.28 due to increased investments in financial products and cash dividends paid[9] - The weighted average return on equity decreased to 1.52%, down 4.39% from the previous year[3] - The company experienced a 95.50% increase in notes receivable, totaling ¥13,245,445.63, attributed to an increase in received bills[6] - Accounts receivable rose to ¥13,245,445.63 from ¥6,775,206.80[15] - Inventory levels rose to CNY 840,279.68, compared to CNY 666,513.20, suggesting increased stock levels[16] - Deferred income tax liabilities increased to CNY 11,603,037.24 from CNY 7,097,065.15, suggesting changes in tax obligations[17]
万邦医药(301520) - 2024 Q3 - 季度财报